CD19 and B-cell chronic lymphocytic leukemia: Beyond cBTKi and BCL2i treatment, patients with CLL/SLL now have access to the FDA approved non-covalent BTKi (ncBTKi) pirtobrutinib as well as the CD19 targeted chimeric antigen receptor T-cell (CAR T-cell) therapy lisocabtagene maraleucel (liso-cel).